Background
swapnil hiremath
The KDIGO CKD 2024 Guidelines Part 1: ...

This week, we will discuss the 2024 KDIGO Guidelines on CKD, part 1. In this section we will discuss the first two chapters on CKD evaluation and risk stratification. Let’s dive in!

The KDIGO CKD 2024 Guidelines Part 1: Evaluation and Risk Stratification
Background
Jade Teakell
Shedding Light on the Dense Matter of C3 ...

This week, we will discuss the role of ApoE in determining the subtypes of C3 Glomerulopathy.

Shedding Light on the Dense Matter of C3 Glomerulopathy
Background
swapnil hiremath
Healing, Hype, or Harm: The NefIgArd trial

This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?

Healing, Hype, or Harm: The NefIgArd trial
Background
Cristina Adriana Popa
PRAECISely Predicting Preeclampsia

This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.

PRAECISely Predicting Preeclampsia
Background
swapnil hiremath
The Worldwide Shadow of Kidney Disease

This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.

The Worldwide Shadow of Kidney Disease

Background

IgA Nephropathy: Testing Steroids Again

IgA Nephropathy: Testing Steroids Again

Stop-IgAN suggested steroids may not be useful in patients with intermediate range proteinuria. Now, in a different population with more proteinuria, TESTING finds a mixed result: some benfit + more adverse events. Should we keep on TESTING? 

Encapsulating Peritoneal Sclerosis: The ISPD Advice

Encapsulating Peritoneal Sclerosis: The ISPD Advice

This week, we will discuss the fresh-off-the-press ISPD guidelines on encapsulating peritoneal sclerosis. We are happy to have support from the ISPD for organizing this - and making the manuscript open, and also the ISPD Vancouver 2018 team, who will be co-hosting the #NephJC chat. 

Can Canaglifozin Communicate Consistency with CANVAS?

Can Canaglifozin Communicate Consistency with CANVAS?

Were the EMPA-REG Renal results chance, or is this a class effect? Let's take a deep dive into CANVAS, published in the NEJM recently, which examined the cardiovascular safety of canaglifozin in type 2 diabetes.